Review Claim by Claim

One-paragraph visual digest (paper’s central claims)

• HPV-associated HNSCC — especially oropharyngeal (HPV16-dominant) — is highly suited for liquid-biopsy monitoring because viral sequences (HPV DNA) act as tumor-specific markers Parisi et al. (review).
• ddPCR is highlighted as the pragmatic frontline assay for surveillance (sensitivity >95%, specificity >98% reported pooled) while NGS/hybrid-capture offers breadth for resistance profiling but at higher cost and complexity Parisi et al. (methods comparison).
• Clinical utility claims: ctDNA kinetics predict treatment response and can detect recurrence months earlier than imaging (median ~3–6 months lead) — supported by cohort studies (e.g., Chera 2019; Jakobsen 2023) Chera et al. 2019 Jakobsen et al. 2023.

1) Strengths of the review

• Comprehensive scope: covers ctDNA (viral/host), CTCs, EVs, assay technologies, pre-analytic factors, costs, and implementation pathways — useful for clinicians and laboratory directors Parisi et al. (scope).
• Clinical orientation: emphasizes ddPCR pragmatism for MRD surveillance and hybrid ddPCR/NGS strategies for cost-effective roll-out — aligned with reproducibility/implementation literature (ISLB, BloodPAC) ISLB perspective (2020).

2) Key limitations / blindspots (critical)

1. Evidence synthesis is narrative (authors state no meta-analysis due to heterogeneity) — paper therefore reports pooled sensitivity/spec numbers (e.g., ddPCR 96% sens) without formal meta-analytic weighting; this constrains quantitative precision and can magnify publication bias effects Parisi et al. (methods).
2. Over-reliance on HPV16-centric assays. Most ctDNA ddPCR assays (and many ddPCR validations) target HPV16 E6/E7; non-HPV16 genotypes (18/31/33) are underrepresented — the review notes decreases in sensitivity for non-HPV16 cases but does not quantify the expected loss across cohorts, an important operational blindspot when generalizing beyond contemporary North American/European OPSCC cohorts where HPV16 predominates Parisi et al. (genotype limitation).
3. Heterogeneity of anatomical sites: review conflates oropharyngeal (OP) HPV+ HNSCC (large evidence base) and non-OP HPV+ disease (far less data). Extrapolating performance metrics from OP-centric cohorts to larynx, hypopharynx, oral cavity risks over-generalization because ctDNA shedding differs by site; the paper flags this but cannot resolve it without prospective site-stratified cohorts Parisi et al. (site heterogeneity).
4. Standardization and pre-analytics are correctly emphasized, but the review could be stronger by providing explicit recommended SOPs (e.g., plasma volumes, tube types, processing time windows, minimum cfDNA yield thresholds) and a minimum reporting checklist for studies to improve comparability; it does cite SPIDIA and multi-center pre-analytic work but stops short of issuing a concise laboratory SOP (opportunity for practical impact) Lampignano et al. 2020 (preanalytics).

3) Contradictions and missing evidence

• Claim: ddPCR >95% sensitivity in multiple cohorts. Reality: high sensitivity appears robust in advanced disease and in OP cohorts, but sensitivity drops in small-volume/early tumors; the review quotes ranges (some cohorts report >95%) but does not present stratified sensitivity by stage — important for screening vs surveillance use-cases (surveillance in treated OPSCC is a stronger, better-supported claim than population screening) Parisi et al. (sensitivity nuance).
• Screening vs surveillance framing: the review sometimes blends early-detection/multi-cancer screening language (multi-cancer methylation tests) with post-treatment MRD surveillance; these are distinct clinical problems with different acceptable false-positive tolerances and different cost-effectiveness thresholds — authors note this but readers must avoid conflation when applying findings clinically (surveillance is nearer-term feasible than population screening) Ignatiadis et al. 2021 (implementation).

4) Reproducibility, data & methods transparency

As a narrative review the paper depends on primary-study transparency. The authors used QUADAS-2 and Newcastle–Ottawa to screen study quality (good). However, the review does not release an appendix table listing all included studies with extraction fields (sample size, stage, assay platform, primer/probe sequences, limits of detection). Providing such a structured supplement would substantially increase reproducibility and utility for meta-analysts and clinical laboratories Parisi et al. (methods transparency).

5) Practical, evidence-weighted recommendations (what to accept today)

• Adopt ddPCR plasma HPV16 E6/E7 assays for MRD surveillance in treated HPV16+ OPSCC patients where analytic validation exists and teams have SOPs for pre-analytics (specialized cfDNA tubes, prompt processing) — supported by cohort studies (Chera 2019; Jakobsen 2023) Chera et al. 2019 Jakobsen et al. 2023.
• Reserve NGS/hybrid-capture ctDNA when molecular breadth is needed (resistance mechanisms, HPV integration mapping) and when bioinformatics capacity and costs are acceptable; combine with ddPCR for frequent monitoring.
• Do not yet recommend population-level screening using single-analyte plasma HPV ctDNA alone; multi-modal methylation/fragmentomics plus imaging pathways are promising but require prospective randomized evaluation (e.g., multi-cancer early detection literature) Lennon et al. 2020 (MCED feasibility).

6) Concrete ways the paper could be improved (actionable)

• Include a machine-readable Supplementary Table listing every included primary study with structured fields: cohort size, anatomic site, HPV genotype distribution, tumor stage, assay (platform, LOD), sample handling (tube/time), sensitivity/specificity, and follow-up time.
• Provide a concise laboratory SOP (one-page) for blood collection, plasma volume, stabilization tube, processing time, minimum cfDNA yield, and reporting format to improve immediate clinical translation.
• Perform formal meta-analytic weighting for key clinical use-cases (post-treatment MRD surveillance in OPSCC) where studies are sufficiently homogeneous to permit pooling; or, if heterogeneity prevents pooling, present stratified forest plots with study-level data.

7) Confidence & final balanced judgment

Parisi et al. (2025) is a high-quality, clinically-useful narrative review that correctly highlights ddPCR-driven plasma HPV ctDNA surveillance as the most mature near-term application, while honestly exposing gaps (standardization, non-HPV16 genotypes, non-OP sites, prospective validation). I rate the review as useful and accurate for clinicians/labs but limited for policy-level screening recommendations until prospective trials address population screening endpoints and cross-genotype sensitivity.